Japanese Pharmacology & Therapeutics (JPT)
Vol. 38 Suppl. 2 2010
The Record of the Eighteenth Meeting of the Japanese Study Group for the Pathophysiology of the Liver 2010
Opening Remarks
M. Hirano
Jpn Pharmacol Ther 2010 38(s2) s71
2．Investigation of the drug-drug interaction between metformin and a potent MATE Inhibitor, pyrimethamine
S. Ito, et al.
Jpn Pharmacol Ther 2010 38(s2) s77-80
3．Discovery of potential biomarkers for decreased function of transporters
K. Kato, et al.
Jpn Pharmacol Ther 2010 38(s2) s81-3
4．Investigation of the role of OATP1B3 and MRP2 in the docetaxel-induced neutropenia
A. Yamada, et al.
Jpn Pharmacol Ther 2010 38(s2) s85-91
【Discussion 1～4】
Jpn Pharmacol Ther 2010 38(s2) s93-6
5．Investigation of the determinant of the hepatic clearance of atorvastatin with cassette-microdose clinical study
K. Yoshida, et al
Jpn Pharmacol Ther 2010 38(s2) s97-101
6．Positron emission tomography（PET）study for the evaluation of in vivo hepatobiliary transport using［11C］telmisartan
T. Takashima, et al．
Jpn Pharmacol Ther 2010 38(s2) s103-9
7．Analysis of the pharmacokinetic boosting effects of ritonavir to saquinavir
M. Morishita, et al．
Jpn Pharmacol Ther 2010 38(s2) s111-3
8．Investigation of the relationship between drug-induced hepatotoxicity and genotypes of glutathione S-transferases
R. Okada, et al．
Jpn Pharmacol Ther 2010 38(s2) s115-9
【Discussion 5～8】
Jpn Pharmacol Ther 2010 38(s2) s121-4
Special Lecture
Mitochondrial theory of carcinogenesis, chemotherapy & multi-drug resistance
M. Inoue
Jpn Pharmacol Ther 2010 38(s2) s125-6
9．Niemann-pick C2 stimulates the ABCG5/G8-mediated cholesterol secretion
Y. Yamanashi, et al．
Jpn Pharmacol Ther 2010 38(s2) s127-9
10．Nrf2 counteracts cholestatic liver injury via stimulation of hepatic defense systems
H. Sugimoto, et al．
Jpn Pharmacol Ther 2010 38(s2) s131-6
11．Hepatic ABCA1 transporter is up-regulated in cholestatic disorders
Y. Takeyama, et al．
Jpn Pharmacol Ther 2010 38(s2) s137-8
12．Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients
―An analysis based on gender differences―
H. Nakagawa, et al．
Jpn Pharmacol Ther 2010 38(s2) s139-41
13．The association of TIMP-2（tissue inhibitor of metalloproteinase-2）polymorphisms with the progression of liver fibrosis
Y. Ikebuchi, et al．
Jpn Pharmacol Ther 2010 38(s2) s143-5
【Discussion 9～13】
Jpn Pharmacol Ther 2010 38(s2) s147-9
15．Clinical significance cytokeratin 18 fragment, M30 in nonalcoholic steatohepatisis
T. Matono, et al．
Jpn Pharmacol Ther 2010 38(s2) s151-4
16．The relationship between steatosis in skeletal muscle and the development of nonalcoholic steatohepatitis
Y. Kitajima, et al．
Jpn Pharmacol Ther 2010 38(s2) s155-8
17．Follow-up of levovist contrast ultrasound and nuclear medicine tests in patients with NASH
―Pathological correlation―
C. Koreeda, et al．
Jpn Pharmacol Ther 2010 38(s2) s159-64
【Discussion 14～17】
Jpn Pharmacol Ther 2010 38(s2) s165-7
18．Cellular metabolism and redox of citrin deficiency
K. Fukushima, et al．
Jpn Pharmacol Ther 2010 38(s2) s169-
19．Three cases of adult-onset type II citrullinemia
M. Fujimoto, et al．
Jpn Pharmacol Ther 2010 38(s2) s171-9
20．Three cases of adult-onset type II citrullinemia（CTLN2）
K. Okamoto, et al．
Jpn Pharmacol Ther 2010 38(s2) s181-7
21．Gene analysis of the hydroxymethylbilane synthase in Japanese patients with acute intermittent porphyria
N. Maeda, et al．
Jpn Pharmacol Ther 2010 38(s2) s189-2
【Discussion 18～22】
Jpn Pharmacol Ther 2010 38(s2) s193-5
Closing Remarks
S. Sakisaka
Jpn Pharmacol Ther 2010 38(s2) s197